J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial

Johnson & Johnson (J&J) has reported promising results from the Phase II DAHLIAS study of nipocalimab, a neonatal crystallisable fragment receptor (FcRn) blocker in treating moderate-to-severe Sjögren’s disease (SjD).